Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: Tissue microarray analysis of immunostaining scores with clinicopathological parameters

Disease Markers

Volumn 24, Issue 2, 2008, Pages 89-99

  Tsai, Wen Chiuan ^a   Chu, Chi Hong ^a   Yu, Cheng Pin ^a   Sheu, Lai Fa ^a   Chen, Ann ^a   Chiang, Hung ^a   Jin, Jong Shiaw ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Atypical ductal hyperplasia; Ductal carcinoma in situ; Invasive ductal carcinoma; Matriptase; Survivin

Indexed keywords

MATRIPTASE; SURVIVIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOMA IN SITU; CHINESE; CONTROLLED STUDY; FEMALE; FIBROADENOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY;

EID: 38349102468     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/945197     Document Type: Article

References (45)

1. F.A. Tavassoli and P. Devilee, eds, World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of the Breast and Female Genital Organs, Lyon: IARC Press, 2004.
2. N.M. Almasri and M. Al Hamad, Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan, Breast Cancer Res 7 (2005), R598-R604.
3. J.F. Simpson and D.L. Page, Pathology of preinvasive and excellent prognosis breast cancer, Curr Opin Oncol 13 (2001), 426-430.
4. C.Y. Lin, J. Anders, M. Johnson et al., Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity, J Biol Chem 274 (1999), 18231-18236.
5. T. Takeuchi, M.A. Shuman and C.S. Craik, Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue, Proc Natl Acad Sci USA 96 (1999), 11054-11061.
6. H. Tanimoto, L.J. Underwood, Y. Wang et al., Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention, Tumour Biol 22 (2001), 104-114.
7. Y.E. Shi, J. Torri, L. Yieh et al., Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells, Cancer Res 53 (1993), 1409-1415.
8. C.Y. Lin, J.K. Wang, J. Torri et al., Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization, J Biol Chem 272 (1997), 9147-9152.
9. C.Y. Lin, J. Anders, M. Johnson et al., Purification and characterization of a complex containing matriptase and a Kunitztype serine protease inhibitor from human milk, J Biol Chem 274 (1999), 18237-18242.
10. S.L. Lee, R.B. Dickson and C.Y. Lin, Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease, J Biol Chem 275 (2000), 36720-36725.
11. T. Takeuchi, J.L. Harris, W. Huang et al., Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates, J Biol Chem 275 (2000), 26333-26342.
12. S. Satomi, Y. Yamasaki, S. Tsuzuki et al., A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover, Biochem Biophys Res Commun 287 (2001), 995-1002.
13. J.W. Lee, S. Yong Song, J.J. Choi et al., Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia, Hum Pathol 36 (2005), 626-633.
14. M.D. Oberst, M.D. Johnson, R.B. Dickson et al., Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters, Clin Cancer Res 8 (2002), 1101-1107.
15. C.M. Benaud, M. Oberst, R.B. Dickson et al., Deregulated activation of matriptase in breast cancer cells, Clin Exp Metastasis 19 (2002), 639-649.
16. C. Parr, G. Watkins, R.E. Mansel et al., The hepatocyte growth factor regulatory factors in human breast cancer, Clin Cancer Res 10 (2004), 202-211.
17. N.K. Sah, Z. Khan, G.J. Khan et al., Structural, functional and therapeutic biology of survivin, Cancer Lett 244 (2006), 164-171.
18. G. Ambrosini, C. Adida and D.C. Altieri, A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma, Nat Med 3 (1997), 917-921.
19. J.C. Reed and J.R. Bischoff, BIRinging chromosomes through cell division-and survivin' the experience, Cell 102 (2000), 545-548.
20. J. Tran, J. Rak, C. Sheehan et al., Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells, Biochem Biophys Res Commun 264 (1999), 781-788.
21. O.P. Blanc-Brude, M. Mesri, N.R. Wall et al., Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis, Clin Cancer Res 9 (2003), 2683-2692.
22. J. Tran, Z. Master, J.L. Yu et al.,Arole for survivin in chemoresistance of endothelial cells mediated by VEGF, Proc Natl Acad Sci USA 99 (2002), 4349-4354.
23. B.M. Ryan, G.E. Konecny, S. Kahlert et al., Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1, Ann Oncol 17 (2006), 597-604.
24. P.N. Span, F.C. Sweep, E.T. Wiegerinck et al., Survivin is an independent prognostic marker for risk stratification of breast cancer patients, Clin Chem 50 (2004), 1986-1993.
25. F. Vegran, R. Boidot, C. Oudin et al., Distinct expression of Survivin splice variants in breast carcinomas, Int J Oncol 27 (2005), 1151-1157.
26. F. Vegran, R. Boidot, C. Oudin et al., Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer, Oncogene (2006), article in press.
27. P.N. Span, V.C. Tjan-Heijnen, P. Manders et al., High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer, Breast Cancer Res Treat 98 (2006), 223-230.
28. M.M. Lee, I.Y. Chang, C.F. Horng et al., Breast cancer and dietary factors in Taiwanese women, Cancer Causes Control 16 (2005), 929-937.
29. M.D. Pineda, E. White, A.R. Kristal et al., Asian breast cancer survival in the US: a comparison between Asian immigrants, US-born Asian Americans and Caucasians, Int J Epidemiol 30 (2001), 976-982.
30. P.L. Fitzgibbons, D.L. Page, D. Weaver et al., Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999, Arch Pathol Lab Med 124 (2000), 966-978.
31. M.D. Oberst, L.Y. Chen, K. Kiyomiya et al., HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease, Am J Physiol Cell Physiol 289 (2005), C462-C470.
32. M.D. Oberst, B. Singh, M. Ozdemirli et al., Characterization of matriptase expression in normal human tissues, J Histochem Cytochem 51 (2003), 1017-1025.
33. T. Shimomura, K. Denda, A. Kitamura et al., Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor, J Biol Chem 272 (1997), 6370-6376.
34. H. Kataoka, T. Shimomura, T. Kawaguchi et al., Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment, J Biol Chem 275 (2000), 40453-40562.
35. M. Oberst, J. Anders, B. Xie et al., Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo, Am J Pathol 158 (2001), 1301-1311.
36. H. Tanimoto, L.J. Underwood, Y. Wang et al., Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention, Tumour Biol 22 (2001), 104-114.
37. Y. Xiang, H. Yao, S. Wang et al., Prognostic value of Survivin and Livin in nasopharyngeal carcinoma, Laryngoscope 116 (2006), 126-130.
38. A. Rosato, M. Pivetta, A. Parenti et al., Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma, Int J Cancer (2006), article in press.
39. Zhu H, Chen XP, Zhang WG, et al. Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J Gastroenterol 11 (2005), 3855-3859.
40. U. Bhanot, R. Heydrich, P. Moller et al., Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma, Am J Surg Pathol 30 (2006), 754-759.
41. Abd El-Hameed A. Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst 2005, 17:42-50.
42. Mahotka C, Krieg T, Krieg A, et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002, 100:30-6.
43. Kitamura H, Torigoe T, Honma I, et al. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy. Urology 2006, 67:955-9.
44. Invernizzi R, Travaglino E, Benatti C, et al. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. Eur J Haematol 2006, 76:494-501.
45. Lam JS, Belldegrum AS, Figlin RA. Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy. Clin Cancer Res 2004, 10:6304s-6309s.